179 results
Page 3 of 9
8-K
EX-10.1
oyjjnr nc0gn
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
EX-10.2
40gkbmgd1vcj41w76
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K/A
EX-10.5
2x12gs2p xpeomy4bsuh
1 Oct 20
Departure of Directors or Certain Officers
4:17pm
8-K
EX-10.2
ubea7qz131ir34r6pus
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.3
jcrqy6i1fccr3p
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.1
ez893sjp j7cdd2
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.4
0publmozxnuwu2 eie
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.5
zmr8g
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.1
dp9yqagzrb
19 Jun 20
Departure of Directors or Certain Officers
4:16pm
8-K
EX-10.1
z8v1dc4jhq mz
27 Apr 20
Entry into a Material Definitive Agreement
4:18pm